LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the…Read More
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
